424 related articles for article (PubMed ID: 17591564)
1. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
Macklis RM
Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564
[TBL] [Abstract][Full Text] [Related]
2. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Gordon LI; Witzig TE; Wiseman GA; Flinn IW; Spies SS; Silverman DH; Emmanouilides C; Cripe L; Saleh M; Czuczman MS; Olejnik T; White CA; Grillo-López AJ
Semin Oncol; 2002 Feb; 29(1 Suppl 2):87-92. PubMed ID: 11842394
[TBL] [Abstract][Full Text] [Related]
3. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
4. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
de Nully Brown P; Jurlander J; Lindén O; Hansen M
Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
[TBL] [Abstract][Full Text] [Related]
5. Future directions in radioimmunotherapy for B-cell lymphoma.
Horning SJ
Semin Oncol; 2003 Dec; 30(6 Suppl 17):29-34. PubMed ID: 14710401
[TBL] [Abstract][Full Text] [Related]
6. Development of 131I-tositumomab.
Lewington V
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S50-6. PubMed ID: 15786026
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma.
Ghobrial I; Witzig T
Oncology (Williston Park); 2004 May; 18(5):623-30; discussion 633-4, 637-8, 640. PubMed ID: 15209190
[TBL] [Abstract][Full Text] [Related]
8. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
9. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
Grillo-López AJ
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists.
Macklis RM; Pohlman B
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):833-41. PubMed ID: 16965871
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
Alcindor T; Witzig TE
Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy for B-cell non-hodgkin lymphomas.
Tomblyn M
Cancer Control; 2012 Jul; 19(3):196-203. PubMed ID: 22710895
[TBL] [Abstract][Full Text] [Related]
13. Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
Meredith RF; Knox SJ
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S15-22. PubMed ID: 16979433
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
Kawashima H
ScientificWorldJournal; 2014; 2014():492061. PubMed ID: 25379535
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy in a radiation oncology environment: building a multi-specialty team.
Macklis RM
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S4-6. PubMed ID: 16979439
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update.
Cicone F; Santo G; Bodet-Milin C; Cascini GL; Kraeber-Bodéré F; Stokke C; Kolstad A
Semin Nucl Med; 2023 May; 53(3):413-425. PubMed ID: 36635112
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Witzig TE
Best Pract Res Clin Haematol; 2006; 19(4):655-68. PubMed ID: 16997175
[TBL] [Abstract][Full Text] [Related]
18. Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).
Hernandez MC; Knox SJ
Semin Oncol; 2003 Dec; 30(6 Suppl 17):6-10. PubMed ID: 14710397
[TBL] [Abstract][Full Text] [Related]
19. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
Witzig TE
Semin Oncol; 2003 Dec; 30(6 Suppl 17):11-6. PubMed ID: 14710398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
